AstraZeneca(US:AZN) Di Yi Cai Jing·2026-01-29 11:01Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to enhance its drug production and R&D capabilities, leveraging China's scientific research strengths and advanced manufacturing [1][3] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, aiming to bring China's innovative results to a global audience [3] - AstraZeneca's CEO highlighted that this investment marks a new chapter in the company's development in China, recognizing the country as a significant force in scientific innovation and global public health [3] Group 2: Strategic Initiatives - The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline that benefits patients with cancer, blood diseases, and autoimmune disorders [3] - AstraZeneca aims to become the first multinational pharmaceutical company with end-to-end cell therapy capabilities in China [3] Group 3: Previous Investments - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - As of January this year, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [3]